Prediction markets and patients
Could clinical trial betting act as insurance for patients?
The patient-hedge argument is more thoughtful than ordinary speculation: if the drug works, the participant may benefit; if it fails, a market payout could help the family. But that does not make a bet equivalent to insurance.
- Kalshi and AppliedXL launched a limited pilot for selected clinical trial outcomes and FDA decisions in July 2026.
- Kalshi says participants in the relevant trials are barred from trading, and initial trial markets are listed after enrollment closes.
- Polymarket has carried biopharma-related contracts, while Endpoint Arena entered the field using paper trading rather than real-money positions.
- The current Clinical Trial Failures database contains 23,617 stopped records, but only 1,821 (7.7%) carry efficacy/futility or safety signals.
- A market-implied probability is not clinical evidence, a patient prognosis, insurance, or medical advice.
The strongest argument for these markets
Most criticism of clinical trial prediction markets begins with the obvious concern: money tied to a trial result can create incentives around an experiment whose first obligation is to patients and reliable evidence. That concern is valid. Still, there is a more sympathetic argument worth taking seriously.
A participant may enter a trial hoping that an experimental drug extends life or improves health. If the trial succeeds, the hoped-for benefit is medical. If it fails, a position paying out on failure could leave money for the participant or family. Framed this way, the contract looks less like entertainment and more like an event-specific hedge.
Why the insurance analogy feels plausible
Insurance transfers a defined financial risk. The proposed hedge tries to do something similar: offset disappointment from one outcome with a payout from the opposite outcome. It also recognizes a real asymmetry. Trial participants accept visits, uncertainty, inconvenience, and sometimes substantial physical burdens, while the broader system captures much of the scientific and commercial value.
The argument therefore points to a legitimate problem. Participants and families can bear costs that standard reimbursement does not fully address. The difficult question is whether a tradable prediction contract is a defensible way to correct that imbalance.
A prediction-market position is not insurance
The analogy breaks down quickly. Insurance has defined coverage, regulated disclosures, underwriting rules, and a payout tied to the policyholder's loss. A prediction-market contract pays according to narrowly written resolution criteria. A Phase III trial could meet its primary endpoint while one participant receives no benefit. It could miss the endpoint while that participant improves. The market event and the patient's outcome are not the same thing.
The hedge is also not guaranteed. The participant must choose a contract, position size, timing, and price, and can lose the stake. A family facing serious illness should not need trading skill, spare capital, or tolerance for gambling risk to receive support for contributing to research.
The current platforms do not offer this patient hedge
Kalshi and AppliedXL launched a limited biopharma pilot in July 2026 covering selected clinical trial outcomes and FDA decisions. The initial design focuses on clearly defined late-stage events and public resolution sources. Importantly, Kalshi says trial participants are barred from trading, and clinical-trial markets are listed only after enrollment has closed.
Polymarket has also carried biopharma-related contracts. Endpoint Arena entered the field with trial-focused markets but, at the time of reporting, used paper trading rather than real money. These are not patient insurance products. They are forecasting or trading venues with different rules, access models, and regulatory positions.
The integrity problem remains
Allowing enrolled participants to take positions would create the very conflict the hedge is meant to soften. Trial behavior can affect adherence, reporting, retention, endpoint assessment, and data quality. Even when one person cannot change the result, a financial interest in failure or success complicates informed consent and public trust.
The risk is not limited to deliberate manipulation. Market prices could influence participant expectations, investigator behavior, enrollment, or the interpretation of ambiguous outcomes. A price is a view produced by traders. It is not clinical evidence, a prognosis, or a substitute for the protocol and source data.
The better answer is direct participant protection
I do not dismiss the hedge argument as crass. It identifies something important: participants should not carry research burdens while being left financially exposed. I simply do not think a wager is the right mechanism.
A better system would provide transparent compensation for time and inconvenience, travel and wage support, treatment for research-related injury, post-trial access where appropriate, and clearly funded family support. Those benefits can be guaranteed without asking a patient to bet against the study they joined. Prediction markets may produce an additional public signal, but they should remain separate from patient protection and clinical decision-making.
What the current platforms actually provide
| Platform | Relevant model |
|---|---|
| Kalshi | Real-money event contracts; limited biopharma pilot with participant restrictions |
| Polymarket | Prediction contracts, including biopharma and FDA-related events |
| Endpoint Arena | Trial-focused forecasting in pilot mode using paper trading |
Why historical context still matters
| Dataset signal | Current records |
|---|---|
| Stopped clinical trial records | 23,617 |
| Likely biological failure signals | 1,821 |
| Efficacy/futility signals | 1,100 |
| Safety signals | 721 |
Continue from here
FAQ
Can clinical trial participants trade on Kalshi's trial markets?
Kalshi has said participants in the relevant trials are barred from trading in its initial biopharma markets. The initial trial contracts are also listed after enrollment has closed.
Is betting on trial failure the same as buying insurance?
No. A prediction contract settles on defined market criteria rather than the individual patient's medical or financial loss, and the trader can lose the money used to take the position.
Could prediction markets still provide useful information?
They may provide a market-implied probability for a narrowly defined event, but its quality depends on participation, liquidity, information, contract design, and trader independence. It is not clinical evidence or medical advice.
Source note: counts are generated from the current ClinicalTrials.gov-derived stopped-trial dataset used by ClinicalTrialFailures.com. These labels are analytical screening signals, not medical advice.